参考文献

1.Menter A，Gottlieb A，Feldman SR，et al.Guidelines of care for the management of psoriasisand psoriatic arthritis：Section 1.Overview of psoriasis and guidelines of care for the treatmentof psoriasis with biologics.J Am Acad Dermatol，2008，58（5）：826-850.Epub 2008／04／22.eng.

2.Enamandram M，Kimball AB.Psoriasis epidemiology：the interplay of genes and the environ-ment.J Invest Dermatol，2013，133（2）：287-289.

3.Ding XL，Wang TL，Shen YW，etal.Prevalence of Psoriasis in China：An Epidemiological Sur-vey in Six Provinces.Chin JDerm Venereol，2010，07：598-601.

4.Neimann AL，Shin DB，Wang X，etal.Prevalence of cardiovascular risk factors in patientswithpsoriasis.JAm Acad Dermatol，2006，55（5）：829-835.Epub 2006／10／21.eng.

5.Gelfand JM，Weinstein R，Porter SB，et al.Prevalence and treatment of psoriasis in the UnitedKingdom：a population-based study.Arch Dermatol，2005，141（12）：1537-1541.Epub 2005／12／21.eng.

6.Berger K，Ehlken B，Kugland B，et al.Cost-of-illness in patients with moderate and severechronic psoriasis vulgaris in Germany.J Dtsch Dermatol Ges，2005，3（7）：511-518.Epub2005／06／22.eng.

7.Schoffski O，Augustin M，Prinz J，et al.Costs and quality of life in patients with moderate tosevere p laque-type psoriasis in Germany：amulti-center study.JDtsch Dermatol Ges，2007，5（3）：209-218.Epub 2007／03／07.eng.

8.Beyer V，Wolverton SE.Recent trends in systemic psoriasis treatment costs.Arch Dermatol，2010，146（1）：46-54.Epub 2010／01／20.eng.

9.Krueger G，Koo J，LebwohlM，et al.The impact of psoriasis on quality of life：results of a 1998National Psoriasis Foundation patient-membership survey.Arch Dermatol，2001，137（3）：280-284.Epub 2001／03／20.eng.

10.Russo PA，Ilchef R，Cooper AJ.Psychiatricmorbidity in psoriasis：a review.Australas JDer-matol，2004，45（3）：155-159.Epub 2004／07／15.eng.

11.Sampogna F，Tabolli S，Abeni D.Living with psoriasis：prevalence of shame，anger，worry，andproblems in daily activities and social life.Acta Derm Venereol，2012，92（3）：299-303.Epub2012／06／09.eng.

12.Rapp SR，Feldman SR，Exum ML，et al.Psoriasis causes as much disability as other majormedical diseases.JAm Acad Dermatol，1999，41（3 Pt1）：401-407.Epub 1999／08／25.eng.

13.Clarke P.Psoriasis.Aust Fam Physician，2011，40（7）：468-473.Epub 2011／07／12.eng.

14.Setty AR，Curhan G，Choi HK.Obesity，waist circumference，weight change，and the risk ofpsoriasis in women：Nurses’ Health Study Ⅱ.Arch Intern Med，2007，167（15）：1670-1675.Epub 2007／08／19.eng.

15.Herron MD，Hinckley M，Hoffman MS，etal.Impactof obesity and smoking on psoriasis pres-entation and management.Arch Dermatol，2005，141 （12）：1527-1534.Epub 2005／12／21.eng.

16.Higgins E.Alcohol，smoking and psoriasis.Clin Exp Dermatol，2000，25（2）：107-110.Epub2000／03／25.eng.

17.Naldi L，Chatenoud L，Linder D，et al.Cigarette smoking，body mass index，and stressful lifeevents as risk factors for psoriasis：results from an Italian case-control study.J Invest Derma-tol，2005，125（1）：61-67.Epub 2005／06／29.eng.

18.Perera GK，Di Meglio P，Nestle FO.Psoriasis.Annu Rev Pathol，2012，7：385-422.Epub2011／11／08.eng.

19.Naldi L，Parazzini F，Peli L，etal.Dietary factors and the risk of psoriasis.Results of an Ital-ian case-control study.Br JDermatol，1996，134（1）：101-106.Epub 1996／01／01.eng.

20.Nast A，BoehnckeWH，M rowietz U，et al.S3-Guidelines on the treatment of psoriasis vulgaris（English version）.Update.JDtsch Dermatol Ges，2012，10（Suppl 2）：S1-95.Epub 2012／04／12.eng.

21.Nestle FO，Kaplan DH，Barker J.Psoriasis.N Engl JMed，2009，361（5）：496-509.Epub2009／07／31.eng.

22.Gottlieb A，Korman NJ，Gordon KB，etal.Guidelines of care for themanagementof psoriasisand psoriatic arthritis：Section 2.Psoriatic arthritis：overview and guidelines of care for treat-mentwith an emphasis on the biologics.JAm Acad Dermatol，2008，58（5）：851-564.Epub2008／04／22.eng.

23.National Clinical Guideline Centre（2012）.Psoriasis Assessment and management of psoria-sis.London：Royal College of Physicians（UK），2012.

24.Marks R，Barton SP，Shuttleworth D，et al.Assessment of disease progress in psoriasis.ArchDermatol，1989，125（2）：235-240.PubMed PMID：2643928.Epub 1989／02／01.eng.

25.Finlay A Y，Khan G K.Dermatology Life Quality Index（DLQI）—a simple practicalmeasurefor routine clinical use.Clin Exp Dermatol，1994，19（3）：210-216.PubMed PMID：8033378.Epub 1994／05／01.eng.

26.Robinson A，KardosM，Kimball A B.Physician Global Assessment（PGA）and Psoriasis Areaand Severity Index（PASI）：Why do both？ Asystematic analysis of randomized controlledtrials of biologic agents formoderate to severe plaque psoriasis.JAm Acad Dermatol，2012，66（3）：369-375.PubMed PMID：22041254.Epub 2011／11／02.eng.

27.Therapeutic Goods Administration，Department of Health and Ageing.Guideline on clinicalinvestigation ofmedicinal products indicated for the treatment of psoriasis.2004.Retrivedfrom http：／www.tga.gov.au／clinical-efficacy-and-safety-guidelines.

28.广东省中医标准化技术委员会.DB44／T1423-2014寻常型银屑病中西医结合诊疗指南.广州：广东省质量技术监督局，2014.

29.Menter A，Korman N J，Elmets CA，etal.Guidelines of care for themanagement of psoriasisand psoriatic arthritis，Section 5.Guidelines of care for the treatmentof psoriasiswith photo-therapy and photochemotherapy.J Am Acad Dermatol，2010，62（1）：114-135.PubMedPMID：19811850.Epub 2009／10／09.Eng.